PE20191349A1 - Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos - Google Patents
Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismosInfo
- Publication number
- PE20191349A1 PE20191349A1 PE2019001676A PE2019001676A PE20191349A1 PE 20191349 A1 PE20191349 A1 PE 20191349A1 PE 2019001676 A PE2019001676 A PE 2019001676A PE 2019001676 A PE2019001676 A PE 2019001676A PE 20191349 A1 PE20191349 A1 PE 20191349A1
- Authority
- PE
- Peru
- Prior art keywords
- piperidine
- amino
- alkyl
- related methods
- compounds
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 AMINO Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- XVIAPHVAGFEFFN-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical compound N#CC1=CN=CN=C1 XVIAPHVAGFEFFN-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
SE REFIERE A COMPUESTOS SUSTITUIDOS CON PIPERIDINA DE FORMULA (I) DONDE X1 ES CH2 Y X2 ES NR2 O X1 ES NR2 Y X2 ES CH2; R1 ES H, ALQUILO(C1-C4), HALOGENO O CN; R2 ES H, ALQUILO(C1-C8) O HALOALQUILO(C1-C8); R3 ES ALQUILO(C1-C8), O R2 Y UN ADYACENTE R3, O R3 Y UN ADYACENTE R3, JUNTO CON LOS ATOMOS DEL ANILLO AL QUE ESTAN UNIDOS, FORMAN UN ANILLO DE CICLOALQUILO O HETEROCICLO FUSIONADO DE CINCO O SEIS MIEMBROS; n ES DE 0 A 4. SON COMPUESTOS PREFERIDOS: (R)-6-((6-AMINO-5-METILPIRIMIDIN-4-IL)AMINO)-1',8-DIMETIL-2H-ESPIRO[IMIDAZO[1,5-a]PIRIDINA-3,3'-PIPERIDINA]-1,5-DIONA; (R)-4-AMINO-6-((1',8-DIMETIL-1,5-DIOXO-1,5-DIHIDRO-2H-ESPIRO[IMIDAZO[1,5-a]PIRIDINA-3,3'-PIPERIDIN]-6-IL)AMINO)PIRIMIDINA-5-CARBONITRILO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA QUE INTERACTUAN CON MAP QUINASA (MnK) SIENDO UTILES EN EL TRATAMIENTO DE CANCER
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762458671P | 2017-02-14 | 2017-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20191349A1 true PE20191349A1 (es) | 2019-09-30 |
Family
ID=63106539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2019001676A PE20191349A1 (es) | 2017-02-14 | 2018-02-13 | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos |
Country Status (21)
Country | Link |
---|---|
US (3) | US20180228803A1 (es) |
EP (1) | EP3582776B1 (es) |
JP (2) | JP2020507588A (es) |
KR (1) | KR20190117013A (es) |
CN (1) | CN110719781A (es) |
AU (2) | AU2018220840A1 (es) |
BR (1) | BR112019016707A2 (es) |
CA (1) | CA3053493A1 (es) |
CL (1) | CL2019002297A1 (es) |
CO (1) | CO2019009423A2 (es) |
DK (1) | DK3582776T3 (es) |
EA (1) | EA201991894A1 (es) |
ES (1) | ES2969988T3 (es) |
FI (1) | FI3582776T3 (es) |
IL (1) | IL268619B (es) |
MX (1) | MX2019009653A (es) |
PE (1) | PE20191349A1 (es) |
PH (1) | PH12019550140A1 (es) |
SG (1) | SG11201907356SA (es) |
TW (1) | TWI762579B (es) |
WO (1) | WO2018152117A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20191349A1 (es) | 2017-02-14 | 2019-09-30 | Effector Therapeutics Inc | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos |
KR20210102211A (ko) | 2018-10-24 | 2021-08-19 | 이펙터 테라퓨틱스, 인크. | Mnk 억제제의 결정질 형태 |
CN111484494B (zh) * | 2019-01-29 | 2022-09-13 | 诺沃斯达药业(上海)有限公司 | 抑制mnk1和mnk2的多环化合物 |
WO2021098691A1 (zh) | 2019-11-18 | 2021-05-27 | 南京明德新药研发有限公司 | 作为mnk抑制剂的吡咯并三嗪类化合物 |
WO2022038563A1 (en) * | 2020-08-20 | 2022-02-24 | Hepagene Therapeutics (HK) Limited | Mnk inhibitors |
KR20240004828A (ko) * | 2021-05-08 | 2024-01-11 | 점보 드러그 뱅크 컴퍼니 리미티드 | 피롤로트리아진 화합물의 염 형태, 이의 결정형 및 이의 제조 방법 |
CN114736205B (zh) * | 2022-03-31 | 2023-03-03 | 武汉九州钰民医药科技有限公司 | 化合物Tomivosertib的制备方法 |
CN114853756B (zh) * | 2022-03-31 | 2023-03-28 | 武汉九州钰民医药科技有限公司 | 化合物Tomivosertib的制备工艺 |
WO2024017229A1 (zh) * | 2022-07-19 | 2024-01-25 | 成都嘉葆药银医药科技有限公司 | 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用 |
CN116425750A (zh) * | 2023-02-10 | 2023-07-14 | 诺沃斯达药业(上海)有限公司 | 一种mnk抑制剂化合物的盐、晶体及其制备方法 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5491144A (en) | 1991-05-30 | 1996-02-13 | Ciba-Geigy Corporation | Substituted diaminophthalimides and analogues |
DE60219788T2 (de) | 2001-06-05 | 2008-01-17 | Lilly Icos Llc, Wilmington | Tetrazyklische verbindungen als pde5-inhibitoren |
ES2359233T3 (es) | 2001-10-29 | 2011-05-19 | Boehringer Ingelheim International Gmbh | Proteínas homólogas de la quinasa mnk implicadas en la regulación de la homeostasis energética y en el metabolismo organular. |
US20050012622A1 (en) | 2003-05-19 | 2005-01-20 | Sutton William R. | Monitoring and control of sleep cycles |
TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
WO2006135783A2 (en) | 2005-06-10 | 2006-12-21 | Wisconsin Alumni Research Foundation | Compositions and methods for modulating angiogenesis |
JP2009509921A (ja) | 2005-08-12 | 2009-03-12 | アストラゼネカ アクチボラグ | 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用 |
CN101472912A (zh) | 2006-06-22 | 2009-07-01 | 比奥维特罗姆上市公司 | 作为mnk激酶抑制剂的吡啶和吡嗪衍生物 |
EP1889847A1 (en) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
ES2485040T3 (es) | 2007-03-16 | 2014-08-12 | The Scripps Research Institute | Inhibidores de cinasa de adhesión focal |
GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
JP2011504474A (ja) | 2007-11-22 | 2011-02-10 | ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルツハイマー氏病を治療するためのMnkインヒビターの使用 |
JP2009173629A (ja) | 2007-12-21 | 2009-08-06 | Banyu Pharmaceut Co Ltd | Rsk1阻害作用を有する新規スピロインダン誘導体 |
WO2009112445A1 (en) | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
AU2009286734A1 (en) | 2008-08-26 | 2010-03-04 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
EP2355819A2 (en) | 2008-11-12 | 2011-08-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating a mnk |
US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β-類澱粉生成之化合物 |
EP2462123B1 (en) | 2009-08-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
US8604217B2 (en) | 2009-11-12 | 2013-12-10 | Selvita S.A. | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
WO2011106168A1 (en) | 2010-02-24 | 2011-09-01 | Dcam Pharma Inc | Purine compounds for treating autoimmune and demyelinating diseases |
MA34553B1 (fr) | 2010-10-01 | 2013-09-02 | Bayer Ip Gmbh | Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué |
ES2716158T3 (es) | 2010-11-30 | 2019-06-10 | Gilead Pharmasset Llc | 2'-spiro-nucleótidos para el tratamiento de hepatitis C |
US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
US9447087B2 (en) | 2011-09-23 | 2016-09-20 | University Of Utah Research Foundation | Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders |
AR089489A1 (es) | 2011-12-30 | 2014-08-27 | 27 | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas |
CA2868966C (en) | 2012-03-29 | 2021-01-26 | Francis Xavier Tavares | Lactam kinase inhibitors |
GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
EP2852593A1 (en) | 2012-05-21 | 2015-04-01 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyrimidines |
TW201412740A (zh) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
WO2014072244A1 (en) | 2012-11-09 | 2014-05-15 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted quinazolines for pharmaceutical compositions |
GB2508652A (en) | 2012-12-07 | 2014-06-11 | Agency Science Tech & Res | Heterocyclic piperazine derivatives |
EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
EP2958920A1 (en) | 2013-02-20 | 2015-12-30 | Bayer Pharma Aktiengesellschaft | Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors |
TW201605867A (zh) | 2013-11-20 | 2016-02-16 | 拜耳製藥公司 | 噻吩并嘧啶 |
TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | MnK抑制劑及其相關方法 |
TN2017000258A1 (en) | 2014-12-19 | 2018-10-19 | Bayer Pharma AG | Pyrazolopyridinamines as mknk1 and mknk2 inhibitors |
JP6681919B2 (ja) | 2015-04-20 | 2020-04-15 | イーフェクター セラピューティクス, インコーポレイテッド | がんおよび感染症を処置する際に使用するための免疫チェックポイントモジュレーターの阻害剤 |
US10112955B2 (en) | 2015-10-29 | 2018-10-30 | Effector Therapeutics, Inc. | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 |
CN108602814A (zh) | 2015-10-29 | 2018-09-28 | 效应治疗股份有限公司 | 抑制mnk1和mnk2的吡咯并-、吡唑并-、咪唑并-嘧啶和吡啶化合物 |
GB201520499D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
WO2017087808A1 (en) | 2015-11-20 | 2017-05-26 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers |
GB201520500D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
US20170191136A1 (en) | 2015-12-31 | 2017-07-06 | Effector Therapeutics, Inc. | Mnk biomarkers and uses thereof |
JP2020504715A (ja) * | 2016-12-19 | 2020-02-13 | エピザイム,インコーポレイティド | Ehmt2阻害剤としてのアミン置換複素環化合物およびその使用方法 |
PE20191349A1 (es) | 2017-02-14 | 2019-09-30 | Effector Therapeutics Inc | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos |
WO2018218038A1 (en) | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
JP2021503478A (ja) | 2017-11-16 | 2021-02-12 | ノバルティス アーゲー | 組み合わせ治療 |
WO2019103926A1 (en) | 2017-11-21 | 2019-05-31 | Saint Louis University | P38 inhibitors for the treatment of fshd |
KR20210102211A (ko) | 2018-10-24 | 2021-08-19 | 이펙터 테라퓨틱스, 인크. | Mnk 억제제의 결정질 형태 |
-
2018
- 2018-02-13 PE PE2019001676A patent/PE20191349A1/es unknown
- 2018-02-13 DK DK18754330.1T patent/DK3582776T3/da active
- 2018-02-13 TW TW107105327A patent/TWI762579B/zh active
- 2018-02-13 CN CN201880011685.6A patent/CN110719781A/zh active Pending
- 2018-02-13 AU AU2018220840A patent/AU2018220840A1/en not_active Abandoned
- 2018-02-13 EP EP18754330.1A patent/EP3582776B1/en active Active
- 2018-02-13 EA EA201991894A patent/EA201991894A1/ru unknown
- 2018-02-13 FI FIEP18754330.1T patent/FI3582776T3/fi active
- 2018-02-13 CA CA3053493A patent/CA3053493A1/en active Pending
- 2018-02-13 KR KR1020197026790A patent/KR20190117013A/ko not_active Application Discontinuation
- 2018-02-13 JP JP2019543809A patent/JP2020507588A/ja active Pending
- 2018-02-13 SG SG11201907356SA patent/SG11201907356SA/en unknown
- 2018-02-13 ES ES18754330T patent/ES2969988T3/es active Active
- 2018-02-13 WO PCT/US2018/018022 patent/WO2018152117A1/en active Application Filing
- 2018-02-13 US US15/895,523 patent/US20180228803A1/en not_active Abandoned
- 2018-02-13 MX MX2019009653A patent/MX2019009653A/es unknown
- 2018-02-13 BR BR112019016707A patent/BR112019016707A2/pt unknown
- 2018-12-27 US US16/233,507 patent/US11083727B2/en active Active
-
2019
- 2019-08-09 PH PH12019550140A patent/PH12019550140A1/en unknown
- 2019-08-11 IL IL268619A patent/IL268619B/en unknown
- 2019-08-13 CL CL2019002297A patent/CL2019002297A1/es unknown
- 2019-08-29 CO CONC2019/0009423A patent/CO2019009423A2/es unknown
-
2021
- 2021-08-06 US US17/396,187 patent/US11878015B2/en active Active
-
2022
- 2022-04-29 AU AU2022202864A patent/AU2022202864B2/en active Active
- 2022-09-29 JP JP2022156442A patent/JP2022185050A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL268619A (en) | 2019-10-31 |
AU2022202864A1 (en) | 2022-05-19 |
DK3582776T3 (da) | 2024-01-08 |
US11083727B2 (en) | 2021-08-10 |
JP2020507588A (ja) | 2020-03-12 |
SG11201907356SA (en) | 2019-09-27 |
BR112019016707A2 (pt) | 2020-04-07 |
CO2019009423A2 (es) | 2019-09-09 |
JP2022185050A (ja) | 2022-12-13 |
FI3582776T3 (fi) | 2024-01-03 |
EP3582776A1 (en) | 2019-12-25 |
TWI762579B (zh) | 2022-05-01 |
AU2022202864B2 (en) | 2024-06-06 |
CN110719781A (zh) | 2020-01-21 |
EP3582776A4 (en) | 2020-09-02 |
EP3582776B1 (en) | 2023-11-08 |
PH12019550140A1 (en) | 2020-06-01 |
US20190275039A1 (en) | 2019-09-12 |
MX2019009653A (es) | 2019-12-19 |
KR20190117013A (ko) | 2019-10-15 |
US11878015B2 (en) | 2024-01-23 |
CL2019002297A1 (es) | 2019-11-08 |
WO2018152117A1 (en) | 2018-08-23 |
CA3053493A1 (en) | 2018-08-23 |
US20180228803A1 (en) | 2018-08-16 |
EA201991894A1 (ru) | 2020-02-05 |
ES2969988T3 (es) | 2024-05-23 |
AU2018220840A1 (en) | 2019-09-19 |
IL268619B (en) | 2022-05-01 |
TW201835076A (zh) | 2018-10-01 |
US20220096472A1 (en) | 2022-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20191349A1 (es) | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos | |
PE20170321A1 (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos | |
PE20120224A1 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
PE20190475A1 (es) | Inhibidores de cdk2/4/6 | |
AR063099A1 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
AR107127A1 (es) | Indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
PE20151776A1 (es) | Compuestos de heteroarilo y sus usos | |
AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
PE20170144A1 (es) | 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet | |
AR036716A1 (es) | Un compuesto derivado de bencimidazolidinona, metodos que lo utilizan, una composicion farmaceutica que lo comprende y uso de dicho compuesto o composicion | |
AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
PE20081152A1 (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 | |
PE20060185A1 (es) | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA | |
AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
ES2686501T3 (es) | Pirazolo[1,5-a]piridinas sustituidas como inhibidores de la quinasa del receptor de tropomiosina (Trk) | |
AR081252A1 (es) | Compuestos para el tratamiento del sindrome metabolico | |
AR077434A1 (es) | Compuestos para la reduccion de produccion de beta - amiloide | |
AR078841A1 (es) | Derivados de imidazo(1,2-b) piridazina y su uso como inhibidores de pde10 | |
AR089641A1 (es) | COMPUESTOS BICICLICOS Y SUS USOS COMO INHIBIDORES DUALES DE c-SRC/JAK | |
AR044499A1 (es) | Pirimidinas sustituidas con indano inhibidoras de la replicacion del hiv | |
AR043181A1 (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxiptamina-6 | |
AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. |